Business Description
Biomea Fusion Inc
NAICS : 325412
SIC : 2834
ISIN : US09077A1060
Total Employee Number:
37Compare
Compare
Traded in other countries / regions
BMEA.USA Index Membership
Russell 2000Russell 2000Russell 3000 IPO Date
2021-04-16Description
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 39.71 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.6 | |||||
3-Year EPS without NRI Growth Rate | 18.5 | |||||
3-Year FCF Growth Rate | 14.7 | |||||
3-Year Book Growth Rate | -51.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.5 | |||||
9-Day RSI | 50.48 | |||||
14-Day RSI | 55.01 | |||||
3-1 Month Momentum % | 13.79 | |||||
6-1 Month Momentum % | 5.6 | |||||
12-1 Month Momentum % | -34.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.47 | |||||
Quick Ratio | 3.47 | |||||
Cash Ratio | 3.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -34.7 | |||||
Shareholder Yield % | -15.24 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -157.13 | |||||
ROA % | -60.22 | |||||
ROIC % | -1312.91 | |||||
3-Year ROIIC % | -21.97 | |||||
ROC (Joel Greenblatt) % | -2027.99 | |||||
ROCE % | -135.47 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 10.26 | |||||
Price-to-Tangible-Book | 10.26 | |||||
EV-to-EBIT | -2.83 | |||||
EV-to-Forward-EBIT | -1.39 | |||||
EV-to-EBITDA | -2.88 | |||||
EV-to-Forward-EBITDA | -1.39 | |||||
EV-to-Forward-Revenue | 3.03 | |||||
EV-to-FCF | -1.96 | |||||
| Price-to-Net-Current-Asset-Value | 10.91 | |||||
| Price-to-Net-Cash | 12.46 | |||||
Earnings Yield (Greenblatt) % | -35.34 | |||||
FCF Yield % | -37.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BMEA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biomea Fusion Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.497 | ||
| Beta | 1.6098 | ||
| 3-Year Sharpe Ratio | -0.44 | ||
| 3-Year Sortino Ratio | -0.58 | ||
| Volatility % | 72.84 | ||
| 14-Day RSI | 55.01 | ||
| 14-Day ATR ($) | 0.134787 | ||
| 20-Day SMA ($) | 1.7225 | ||
| 12-1 Month Momentum % | -34.65 | ||
| 52-Week Range ($) | 0.8719 - 2.99 | ||
| Shares Outstanding (Mil) | 72.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biomea Fusion Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biomea Fusion Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 48 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-15 11:00 | 1.78 (+3.79%) | ||
| Guidance call for 2026 | 2026-09-10 | 1.85 (-4.90%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 1.23 (+1.65%) | ||
| General meeting for 2026 | 2026-06-10 10:00 | 1.14 (-3.81%) | ||
| Guidance call for 2026 | 2026-06-04 08:10 | 1.30 (-5.11%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 15:00 | 1.25 (-7.41%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 1.54 (-4.94%) | ||
| BMO Metabolic Health Summit | 2026-03-24 11:00 | 1.12 (-2.62%) | ||
| Annual report for 2025 | 2026-03-24 | 1.12 (-2.62%) |
Show
Entries
Biomea Fusion Inc Frequently Asked Questions
What is Biomea Fusion Inc(BMEA)'s stock price today?
The current price of BMEA is $1.75. The 52 week high of BMEA is $2.99 and 52 week low is $0.87.
When is next earnings date of Biomea Fusion Inc(BMEA)?
The next earnings date of Biomea Fusion Inc(BMEA) is 2026-11-04 Est..
Does Biomea Fusion Inc(BMEA) pay dividends? If so, how much?
Biomea Fusion Inc(BMEA) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers